Intellectual Property India Publishes Patent Application for Novel Crystalline Form-M2 Of 2-[3,5-Dichloro-4-(5-Isopropyl-6-Oxo-1,6- Dihydropyridazin-3-Yloxy)phenyl]-3,5-Dioxo-2,3,4,5-Tetrahydro[1,2,4]triazine-6-Carbonitrile And Processes For Their Preparation

MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202441088603 A) filed by Morepen Proprietary Drug Research Private Limited on November 16, 2024, for Novel Crystalline Form-M2 Of 2-[3,5-Dichloro-4-(5-Isopropyl-6-Oxo-1,6- Dihydropyridazin-3-Yloxy)phenyl]-3,5-Dioxo-2,3,4,5-Tetrahydro[1,2,4]triazine-6-Carbonitrile And Processes For Their Preparation.

Inventors include Ravi Shekar Ananthula; Deepa Rani Gopagoni; and Sanjay Suri.

The application for the patent was published on July 10, 2026, under issue no. 28/2026.

Abstract: The present application relates to novel crystalline form M2 of 2-[3,5-dichloro-4- (5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl-oxy) phenyl]-3,5-dioxo-2,3,4,5- tetrahydro [1,2,4] triazine-6-carbonitrile and their processes for the preparations thereof. 2-[3,5-dichloro-4- (5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl-oxy) 10 phenyl]-3,5-dioxo-2,3,4,5-tetrahydro [1,2,4] triazine-6-carbonitrile represented by the following structural formula-1, which is referred to as Resmetirom

Disclaimer: Curated by HT Syndication.